Allena Pharmaceuticals, Inc. R&D Expenses

R&D Expenses of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.

Highlights and Quick Summary

  • R&D Expenses for the quarter ending March 31, 2022 was $7.76 Million (a -1.6% decrease compared to previous quarter)
  • Year-over-year quarterly R&D Expenses decreased by -22.5%
  • Annual R&D Expenses for 2021 was $34.6 Million (a 71.19% increase from previous year)
  • Annual R&D Expenses for 2020 was $20.2 Million (a -45.48% decrease from previous year)
  • Annual R&D Expenses for 2019 was $37.1 Million (a 41.0% increase from previous year)
  • Twelve month R&D Expenses ending March 31, 2022 was $34.6 Million (a -0.08% decrease compared to previous quarter)
  • Twelve month trailing R&D Expenses increased by 16.5% year-over-year
Trailing R&D Expenses for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$34.6 Million $34.6 Million $33.7 Million $29.7 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of Allena Pharmaceuticals, Inc.

Most recent R&D Expensesof ALNA including historical data for past 10 years.

Interactive Chart of R&D Expenses of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $7.76 – – – –
2021 $7.88 $8.93 $10.01 $7.79 $34.61
2020 $6.93 $4.95 $3.81 $4.65 $20.22
2019 $8.72 $10.81 $8.59 $9.13 $37.08
2018 $7.27 $7.32 $5.86 $5.93 $26.3
2017 $4.76 $2.95 $3.46 $4.35 $15.52
2016 – – – $5.26 $20.1
2015 – – – – $11.54

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
© stockrow.com